U.S. markets close in 5 hours 4 minutes

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9100-0.1600 (-7.73%)
As of 10:56AM EDT. Market open.

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
http://www.corbuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Dr. Yuval CohenCEO & Director827.32kN/A1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial Officer528kN/A1958
Dr. Barbara WhiteHead of Research & Chief Medical Officer579.48kN/A1950
Ted JenkinsSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Scott ConstantineSr. Director & Head of Clinical OperationsN/AN/AN/A
Mr. Craig Stuart Millian M.B.A.Chief Commercial OfficerN/AN/A1968
Mr. Dylan WenkeHead of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate Governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.